Structural Heart Devices Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Market Trends and Insights

Rising Prevalence of Structural Heart Diseases In Aging Populations of High-Income Regions

Longer life expectancy in developed economies has expanded the at-risk pool for calcific aortic stenosis and functional mitral regurgitation. Recent registry updates show escalating procedure volumes in patients aged ≥75 years, reinforcing a long-run demand curve. Early-intervention evidence from the EARLY TAVR trial indicates a 20% reduction in rehospitalizations when asymptomatic severe aortic stenosis is treated before symptom onset, broadening the potential candidate base^{[1]Edwards Lifesciences, “2024 Annual Report,” edwards.com}.

Expanding Adoption of Transcatheter Valve Therapies in Low-Risk Patient Cohorts

Five-year follow-up of low-risk patients confirms comparable all-cause mortality between TAVR and surgery, accelerating payer and clinician confidence^{[2]John K. Forrest et al., “5-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients,” Journal of the American College of Cardiology, jacc.org}. Commercial focus has therefore moved to valve durability, paravalvular leak reduction, and hemodynamic performance. Edwards maintains roughly 60% share, Medtronic 28%, and newer entrants such as Abbott are gaining traction with the Navitor system, intensifying differentiation battles.

Favorable Reimbursement Expansion for TAVR And TMVr Procedures

CMS updated its National Coverage Determination to ease data-collection criteria for low-risk TAVR patients, while select European payers now reimburse transcatheter mitral repair outside tertiary centers^{[3]Centers for Medicare & Medicaid Services, “National Coverage Determination for Transcatheter Aortic Valve Replacement,” cms.gov}. Bundled-payment experiments promote efficient device pricing, nudging OEMs toward cost-effective delivery kits and single-use accessory consolidation.

Growth Of Ambulatory Cardiac Surgery Centers Enabling Same-Day Discharge

ASCs handle an increasing mix of left atrial appendage closure and patent foramen ovale repair. Medicare analyses show stroke and mortality below 1% in ASC cohorts, supporting further migration of select valve-in-valve procedures to outpatient settings. Device makers are responding with shorter shaft catheters and simplified sealing mechanisms tailored to resource-constrained facilities.

Increasing Strategic Partnerships Between Device OEMs and AI-Enabled Imaging Firms for Pre-Op Planning

Philips and GE HealthCare have embedded automated 3D quantification into cardiovascular ultrasound, reducing assessment time for tricuspid regurgitation. Improved sizing accuracy limits paravalvular leak, prompting OEMs to bundle imaging analytics with valve systems in value-based contracts.

Limited Access to Skilled Interventional Cardiologists In Emerging Asia & Africa

Rheumatic heart disease remains common in lower-income parts of Asia and Africa, yet procedure capacity is locked in metropolitan hubs. Complex transcatheter mitral replacement requires extensive proctoring that cannot be scaled quickly. Industry training collaborations are underway, but the supply gap continues to dampen adoption momentum in regions with the highest latent demand.

High Up-Front Capital Expenditure for Hybrid Cath-Lab/Or Suites Constraining Smaller Hospitals

Hospitals face negative contribution margins of roughly USD 3,380 per TAVR episode versus positive margins for surgery, discouraging uptake outside high-volume centers^{[4]American Heart Association Journals, “Economic Considerations in Access to Transcatheter Aortic Valve Replacement,” ahajournals.org}. Financing solutions such as revenue-share models and mobile cath-lab units are emerging, yet progress remains gradual.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Structural Heart Devices Market Segment Analysis

Heart valve devices captured 59.35% of 2025 revenue, confirming their anchor role in the structural heart devices market. TAVR’s worldwide revenue is approaching USD 7.0 billion, supported by 10.0% annual growth in the United States. Valve developers focus on lower profile delivery, anti-calcification leaflets, and commissural alignment technologies that improve long-term durability. The structural heart devices market size for valve platforms is projected to advance in lockstep with the rollout of next-generation systems such as Edwards SAPIEN M3, the first transfemoral mitral replacement to secure a CE Mark in 2025.

Occluders and delivery systems are witnessing rapid procedural expansion, particularly in stroke-prevention applications. Abbott’s WATCHMAN FLX portfolio continues to gain operator confidence due to pivot-ready frames and full-circumference sealing. Sales growth is amplified by favorable outpatient reimbursement, making occluders the quickest expanding sub-category within transcatheter repair solutions. New polymer-free nitinol iterations promise even shorter in-hospital stays, placing additional upward pressure on adoption curves across secondary prevention populations. Collectively, these trends maintain the structural heart devices market on its high-single-digit trajectory.

Replacement therapies retained 67.20% share in 2025, helped by robust evidence in low-risk patients and consistent reimbursement across North America and Europe. The structural heart devices market share for TAVR alone is projected to widen further as valve-in-valve and bicuspid approvals unlock new patient cohorts. Edwards estimates 5%-7% TAVR revenue growth for 2025, reaching up to USD 4.4 billion.

Transcatheter repair, steered by clip-based mitral and tricuspid systems, is the structural heart devices market’s fastest-growing procedural class at a 13.95% CAGR. Abbott’s MitraClip generation IV shows reduced residual MR and durable symptomatic relief, underpinning more than 20 supporting trials. FDA clearance of the TriClip and the CE-marked EVOQUE tricuspid valve extend repair technology into previously untreated anatomy, rapidly diversifying manufacturer revenue. This momentum broadens the structural heart devices market size for repair solutions and repositions replacement as one of several viable options rather than the default.

Hospitals and cardiac centers delivered 82.25% of global procedures in 2025, leveraging critical-care capability for complex multivalve interventions. Institutions with dedicated structural heart programs report procedure volume growth of 84% for TAVR/TEER during the 2020-2024 window, underscoring continued centrality of acute-care settings. Yet fixed-cost intensity fuels consolidation, and hospital operators are preparing for a future in which higher-margin elective work migrates off-campus.

Ambulatory surgical centers captured 17.75% of procedures in 2025 but are expanding at 12.32% CAGR. Medicare data show low adverse-event rates, supporting payer confidence and prompting scheduling shifts toward same-day discharge models. Device firms now tailor valve kits with shorter sheaths and pre-mounted delivery handles that can be deployed without full hybrid OR capability. The result is a structural heart devices market dynamic in which ASCs accelerate competitive pricing pressure while expanding patient access, especially for left atrial appendage and PFO closures.

Geography Analysis

North America Structural Heart Devices Market

North America generated 39.45% of global revenue in 2025, anchored by the United States, which performs more than half of all TAVR implants worldwide and maintains roughly 10.0% annual procedure growth. CMS coverage expansion and ASC penetration underpin continued double-digit growth in transcatheter repair volumes. Canadian reimbursement reforms for mitral clip procedures add incremental upside through 2027.

Europe Structural Heart Devices Market

Europe ranks second in value and adopts new technologies swiftly because of centralized procurement and pan-regional CE approvals. The April 2025 CE Mark of the SAPIEN M3 highlights the region’s role as an early commercialization hub for transfemoral mitral solutions. Hospital networks in Germany and France are broadening clip labs and triaging patients into minimally invasive pathways, helping the structural heart devices market size in Europe maintain mid-single-digit growth despite demographic plateauing.

APAC Structural Heart Devices Market

Asia-Pacific posts the fastest CAGR at 10.98% through 2031 as procedure volumes accelerate in China, Australia, and India. India’s structural heart segment, only USD 12.4 million in 2024, is on track for 31% CAGR, driven by domestic OEMs and tier-two private hospitals expanding cath-lab capacity. Diverse disease profiles create varied clinical priorities, from rheumatic-related mitral repair demand in rural areas to degenerative aortic stenosis in urban centers, requiring differentiated go-to-market strategies. Japan’s aging population continues to underpin steady TAVR growth, while South-Korean tertiary centers pilot AI-guided sizing for mitral interventions.

Regulatory Landscape

Structural heart devices are regulated as high-risk implantables in major markets, requiring robust clinical and manufacturing evidence and post-market surveillance. In the United States, the FDA typically routes transcatheter therapies through the PMA pathway, with 2025 and 2026 approvals reinforcing the pace of label expansion and new-category entry, including Abbott's FDA approval of Tendyne TMVR in May 2025 and Edwards Lifesciences' SAPIEN M3 mitral valve replacement approval in December 2025.

In Europe, structural heart implants fall under Regulation (EU) 2017/745 (MDR), with the MDR transition framework extending across device classes into the December 2027 and December 2028 deadlines. In June 2026, the European Commission published delegated regulations (EU 2026/1451 and EU 2026/1359) expanding exemptions for well-established devices, reducing specific clinical investigation and technical documentation assessment burdens for defined mature categories, influencing portfolio strategy between legacy remediation and faster-cycle updates.

Market Opportunities and Future Outlook

New approvals and category openings are expanding the addressable opportunity beyond classic aortic stenosis into historically undertreated anatomies and patient subsets. The regulatory actions include Edwards SAPIEN M3 approval in December 2025 for mitral replacement and JenaValve's March 2026 FDA PMA for Trilogy transcatheter heart valve system for symptomatic, severe aortic regurgitation, creating dedicated transcatheter options in segments that previously depended heavily on surgery and off-label approaches. Abbott's May 2025 FDA approval for Tendyne TMVR in severe mitral annular calcification further illustrates the shift toward therapies designed for complex, higher-risk mitral disease.

Procedure-site evolution and workflow tooling create additional whitespace across end users, particularly where outpatient models and simpler cath-lab setups are gaining traction. The market is also being shaped by clinical-evidence and imaging-driven planning needs, with OEMs and imaging platforms pushing automated quantification and sizing to reduce residual regurgitation and paravalvular leak, which supports broader adoption in hospitals and emerging ambulatory pathways. In parallel, Europe-specific MDR changes in June 2026 that broaden exemptions for defined well-established technologies can lower the regulatory friction for certain mature implantable categories, which may free manufacturer capacity to invest in next-generation mitral and tricuspid transcatheter programs and supporting training infrastructure in regions constrained by specialist availability.